Research ArticleBiology, Engineering, Medicine and Science ReportsVol. 7 | Issue 2 | pp. 21–24Open access
Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy
- 1*
- 1 School of Veterinary Medicine, Univer- sity College Dublin, Belfield, Dublin, IRELAND.
Published in Biology, Engineering, Medicine and Science Reports
Correspondence: Arun HS Kumar
School of Veterinary Medicine, Univer- sity College Dublin, Belfield, Dublin, IRELAND.
Email: arun.kumar@ucd.ie
- Received:
- Apr 14, 2021
- Accepted:
- May 2, 2021
- DOI:
- 10.5530/bems.7.2.8
How to cite
Kumar, A. H. Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy. Biology, Engineering, Medicine and Science Reports, 7(2), 21–24. https://doi.org/10.5530/bems.7.2.8
Abstract
Introduction: Orally bioavailable SARS-CoV-2 antiviral drugs will significantly improve the clinical management of the disease. PF07321332 (PF32) one such orally bioavailable SARS- CoV-2 protease inhibitor which can be helpful to prevent viral replication in the host. Materials and Methods: Hence this study evaluated the network pharmacology of PF32 using established methods to predict its potential safety and efficacy. Results: PF32 was selective against SARS-CoV-2 proteases without any affinity against SARS-CoV-2 RNA polymerase or its spike protein. While PF32 showed pharmacologically relevant affinity against several targets in human tissues. The target profiling of PF32 indicated a fourfold selectivity towards several proteases in human tissues with an affinity (IC50) ranging from 26 to 41 nM. Conclusion: The predicted inhibitory effects of PF32 against both host and viral proteases may have synergistic effects for superior clinical efficacy.
Keywords
Subject
Article metadata
| Title | Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy |
|---|---|
| Authors | Arun HS Kumar |
| Affiliations | School of Veterinary Medicine, Univer- sity College Dublin, Belfield, Dublin, IRELAND. |
| Corresponding author | arun.kumar@ucd.ie |
| Journal | Biology, Engineering, Medicine and Science Reports |
| Volume / Issue | Vol. 7, Issue 2 |
Also in this issue
- Rapid Transformational Therapy (RTT): An Emerging Non-invasive Therapeutic Modalitypp. 13–14
- Molecular Profiling of Neprilysin Expression and its Interactions with SARS-CoV-2 Spike Proteins to Develop Evidence Base Pharmacological Approaches for Therapeutic Interventionpp. 15–20
- Modelling the Efficacy of Neprilysin from Various Species in Degrading Different Amyloid-β peptides: Potential Application in Development of Therapeutics for Alzheimer’s Diseasepp. 25–28